ENFN vs. WK, BLKB, FRSH, BOX, ACIW, BRZE, QTWO, AI, ZETA, and NCNO
Should you be buying Enfusion stock or one of its competitors? The main competitors of Enfusion include Workiva (WK), Blackbaud (BLKB), Freshworks (FRSH), BOX (BOX), ACI Worldwide (ACIW), Braze (BRZE), Q2 (QTWO), C3.ai (AI), Zeta Global (ZETA), and nCino (NCNO). These companies are all part of the "prepackaged software" industry.
Workiva (NYSE:WK) and Enfusion (NYSE:ENFN) are both computer and technology companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, analyst recommendations, earnings, institutional ownership, profitability, media sentiment, risk and dividends.
Workiva received 384 more outperform votes than Enfusion when rated by MarketBeat users. Likewise, 65.50% of users gave Workiva an outperform vote while only 18.75% of users gave Enfusion an outperform vote.
Enfusion has a net margin of 1.40% compared to Enfusion's net margin of -14.20%. Workiva's return on equity of 6.60% beat Enfusion's return on equity.
Workiva has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500. Comparatively, Enfusion has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500.
92.2% of Workiva shares are held by institutional investors. Comparatively, 81.1% of Enfusion shares are held by institutional investors. 3.9% of Workiva shares are held by company insiders. Comparatively, 36.4% of Enfusion shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Workiva had 3 more articles in the media than Enfusion. MarketBeat recorded 4 mentions for Workiva and 1 mentions for Enfusion. Enfusion's average media sentiment score of 0.28 beat Workiva's score of 0.26 indicating that Workiva is being referred to more favorably in the media.
Enfusion has lower revenue, but higher earnings than Workiva. Workiva is trading at a lower price-to-earnings ratio than Enfusion, indicating that it is currently the more affordable of the two stocks.
Workiva currently has a consensus price target of $111.86, suggesting a potential upside of 45.10%. Enfusion has a consensus price target of $9.33, suggesting a potential upside of 8.28%. Given Enfusion's stronger consensus rating and higher possible upside, analysts plainly believe Workiva is more favorable than Enfusion.
Summary
Workiva beats Enfusion on 11 of the 18 factors compared between the two stocks.
Get Enfusion News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENFN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ENFN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Enfusion Competitors List
Related Companies and Tools
